SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Peto R,Boreham J,Clarke M,Davies C,Beral V. UK and USA breast cancer deaths down 25% in year 2000 at ages 20–69 years [letter]. Lancet. 2000; 355: 1822.
  • 2
    Ministry of Health of Brazil. National Cancer Institute Annual Report. Rio de Janeiro, Brazil: Ministry of Health of Brazil; 2002.
  • 3
    Berry DA,Cronin KA,Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005; 353: 17841792.
  • 4
    Kaufmann M,Jonat W,Hilfrich J, et al. Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 study. J Clin Oncol. 2007; 25: 26642670.
  • 5
    Henderson IC,Berry DA,Demetri GD, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003; 21: 976983.
  • 6
    Roche H,Fumoleau P,Spielmann M, et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 trial. J Clin Oncol. 2006; 24: 56645671.
  • 7
    Martin M,Pienkowski T,Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005; 352: 23022313.
  • 8
    Smith I,Procter M,Gelber RD, et al. 2-Year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet. 2007; 369: 2936.
  • 9
    Perez EA,Romond EH,Suman VJ, et al. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer [abstract]. ASCO Annual Meeting Proceedings. J Clin Oncol. 2007; 25: 18S. Abstract 512.
  • 10
    Robert NJ,Eiermann W,Pienkowski T, et al. BCIRG 006: docetaxel and trastuzumab-based regimens improve DFS and OS over AC-T in node positive and high risk node negative HER2 positive early breast cancer patients: quality of life (QOL) at 36 months follow-up [abstract]. ASCO Annual Meeting Proceedings. J Clin Oncol. 2007; 25: 18S. Abstract 19647.
  • 11
    Steinbrook R. Closing the affordability gap for drugs in low-income countries. N Engl J Med. 2007; 357: 19961999.
  • 12
    Schechter CB. Cost effectiveness in context. J Clin Oncol. 2007; 25: 609610.
  • 13
    Woo PPS,Kim JJ,Leung GM. What is the most cost-effective population based cancer screening package for Chinese women? J Clin Oncol. 2007; 25: 617624.
  • 14
    Telli ML,Hunt SA,Carlson RW,Guardino AE. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol. 2007; 25: 35253533.
  • 15
    Slamon DJ,Clark GM,Wong SG,Levin W,Ullrich A,McGuire W. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235: 177182.
  • 16
    Joensuu H,Kellokumpu-Lehtinen PL,Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006; 354: 809820.
  • 17
    National Institutes of Health. Trastuzumab for 6 months or 1 year in treating women with nonmetastatic breast cancer that can be removed by surgery. Clinical trials no. NCT00381901. Bethesda, Md: National Institutes of Health; 2007. Available at:http://clinicaltrials.gov/show/NCT00381901. Accessed on March 13, 2008.
  • 18
    Colleoni M,Maibach R. BIG 1-07/1BCSG 35-07 SOLE Ready for Activation. Breast International Group Newsletter. 2007; 9: 22.
  • 19
    Ratain M,Cohen EE. The value meal: how to save $1700 per month or more on lapatinib. J Clin Oncol. 2007; 25: 33973398.
  • 20
    Pegram MD,Pietras R,Bajamonde A, et al. Targeted therapy: wave of the future. J Clin Oncol. 2005; 23: 17761781.
  • 21
    Sledge GWJr. What is targeted therapy? J Clin Oncol. 2005; 23: 161415.
  • 22
    Paik S,Tang G,Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006; 24: 37263734.
  • 23
    Goetz MP,Knox SK,Suman VJ, et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat. 2007; 101: 113121.
  • 24
    Pegram M,Hsu S,Lewis G, et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene. 1999; 13: 22412251.
  • 25
    Garber JE,Richardson A,Harris LN, et al. Neo-adjuvant cisplatin (CDDP) in “triple-negative” breast cancer (BC). Presented at the 29th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, December 14–17, 2006. Abstract 3074.
  • 26
    Colleoni M,Rocca A,Sandri MT, et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol. 2002; 13: 7380.
  • 27
    Burstein HJ,Spigel D,Kindsvogel K, et al. Metronomic chemotherapy with and without bevacizumab for advanced breast cancer: a randomized phase II study. Presented at the 28th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, December 8–11, 2005. Abstract 4.
  • 28
    National Institutes of Health. Combination chemotherapy after surgery in treating patients with stage I, stage II, or stage III breast cancer. Clinical trials no. NCT00022516. Bethesda, Md: National Institutes of Health; 2007. Available at: http://clinicaltrials.gov/ct2/show/NCT00022516?term=ibcsg+22&rank=1. Accessed on March 13, 2008.
  • 29
    Branco LP,Dienstmann R,Bines J. Megestrol acetate after aromatase inhibitor failure in metastatic breast cancer [abstract]. ASCO Annual Meeting Proceedings. J Clin Oncol. 2006; 24. Abstract 10572.
  • 30
    Lewis JS,Meeke K,Osipo C. Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation. J Natl Cancer Inst. 2005; 23: 17461759.
  • 31
    Blackman DJ,Masi CM. Racial and ethnic disparities in breast cancer mortality: are we doing enough to address the root causes? J Clin Oncol. 2006; 24: 21702178.